JPWO2020232019A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020232019A5
JPWO2020232019A5 JP2021563296A JP2021563296A JPWO2020232019A5 JP WO2020232019 A5 JPWO2020232019 A5 JP WO2020232019A5 JP 2021563296 A JP2021563296 A JP 2021563296A JP 2021563296 A JP2021563296 A JP 2021563296A JP WO2020232019 A5 JPWO2020232019 A5 JP WO2020232019A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532490A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032515 external-priority patent/WO2020232019A1/en
Publication of JP2022532490A publication Critical patent/JP2022532490A/ja
Publication of JPWO2020232019A5 publication Critical patent/JPWO2020232019A5/ja
Pending legal-status Critical Current

Links

JP2021563296A 2019-05-13 2020-05-12 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ Pending JP2022532490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847068P 2019-05-13 2019-05-13
US62/847,068 2019-05-13
PCT/US2020/032515 WO2020232019A1 (en) 2019-05-13 2020-05-12 Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Publications (2)

Publication Number Publication Date
JP2022532490A JP2022532490A (ja) 2022-07-15
JPWO2020232019A5 true JPWO2020232019A5 (hr) 2023-10-05

Family

ID=71069936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563296A Pending JP2022532490A (ja) 2019-05-13 2020-05-12 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ

Country Status (15)

Country Link
US (1) US20220249659A1 (hr)
EP (1) EP3969040A1 (hr)
JP (1) JP2022532490A (hr)
KR (1) KR20220007593A (hr)
CN (1) CN113825527A (hr)
AU (1) AU2020276242A1 (hr)
BR (1) BR112021021713A2 (hr)
CA (1) CA3136568A1 (hr)
CL (1) CL2021002966A1 (hr)
EA (1) EA202192528A1 (hr)
IL (1) IL287728A (hr)
MA (1) MA55965A (hr)
MX (1) MX2021013815A (hr)
SG (1) SG11202111262XA (hr)
WO (1) WO2020232019A1 (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500337A (ja) * 2019-11-04 2023-01-05 イノビオ ファーマシューティカルズ,インコーポレイティド 脳がんを治療するための併用療法
EP4377351A1 (en) * 2021-07-28 2024-06-05 F. Hoffmann-La Roche AG Methods and compositions for treating cancer
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN115869399B (zh) * 2022-12-28 2024-01-12 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
KR100257466B1 (ko) 1994-05-06 2000-07-01 레지날드 쇼트버그 에스. 안토니우스-소도 Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
DE69624824T2 (de) 1995-07-21 2003-09-11 Applied Research Systems Ars Holding N.V., Curacao Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス, インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Pd−1に対する抗体およびその使用
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Pd−l1/pd−l2の同時阻害
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
LT2734551T (lt) 2011-07-24 2018-04-10 Cure Tech Ltd. Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SI2970464T1 (sl) 2013-03-15 2020-08-31 Glaxosmithkline Intellectual Propety Development Limited Anti-LAG-3 vezavni proteini
EP3508502B1 (en) * 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
DK3254110T3 (da) 2015-02-03 2020-05-18 Ventana Med Syst Inc Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
KR20180042412A (ko) 2015-09-02 2018-04-25 이뮤텝 에스.에이.에스. 항-lag-3 항체
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
MA55697A (fr) * 2016-05-18 2022-02-23 Boehringer Ingelheim Int Molécules d'anticorps pour le traitement du cancer
CN110023337B (zh) 2016-10-11 2024-01-05 艾吉纳斯公司 抗lag-3抗体及其使用方法
BR112019006876A2 (pt) 2016-10-13 2019-06-25 Symphogen As anticorpos e composições anti-lag-3
CN110234661B (zh) 2016-12-01 2024-03-29 瑞泽恩制药公司 用于免疫pet成像的放射性标记的抗-pd-l1抗体
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
JP2020513009A (ja) * 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブSymphogen A/S Pd−1、tim−3、およびlag−3を標的とする併用治療

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
JP7126941B2 (ja) がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2022050618A5 (hr)
ES2855798T3 (es) Método de tratamiento del cáncer usando un inhibidor de puntos de control inmunitario; anticuerpo que se une al receptor de muerte programada 1 (pd-1) o al ligando de muerte programada 1 (pd-l1)
RU2695332C2 (ru) Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
JP2022031638A (ja) 放射線療法と併用されるpd-1およびpd-l1に対する拮抗薬を用いたがんの治療法
JP2019515008A5 (hr)
TW201545759A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2020508317A5 (hr)
IL308805A (en) Anti-PD-1 antibodies for the treatment of lung cancer
US20220249659A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
CN117603360A (zh) 用于治疗癌症的多特异性抗体
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
JPWO2019246356A5 (hr)
JPWO2020232019A5 (hr)
JP2023011902A (ja) Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
RU2021128914A (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
RU2024117128A (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4
Pan et al. PS1211 CD22 CAR T-CELL THERAPY IN 34 REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
CA3170733A1 (en) Methods of treating lung cancer by administering a pd-1 inhibitor
CN116887863A (zh) 通过施用pd-1抑制剂治疗肺癌的方法